Clinical trials: COVID, Coronavirus
COVID-19, SARS-CoV-2 Infection
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant, Vaccine Response Impaired
- Trial name
- NCT05124509
- Testing
- Three doses of SARS-CoV-2 BNT162b2 vaccine (observational), Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
- Where
- Chile
- Volunteers
- 147 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Pregnancy Complications, Covid19
Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19
Vitamin D defiency during pregnancy is a major public health problem worldwide; In Spain, the average intake of vitamin D is lower than recommendations in an elevated percentage of the population, ranging from 50 to 95%…
- Trial name
- D-WOMAN (NCT04825093)
- Testing
- Vitamin D supplementation in pregnant women
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
SARS-COV-2 Infections, COVID-19
Fight COVID-19 Trial
A 6-Week Prospective, Open label, Randomized, in Multicenter Study of, Oseltamivir 300mg per day plus Hydroxychloroquine 800 mg per day versus Combination of Lopipinavir 800mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5…
- Trial name
- FIGHT-COVID-19 (NCT04303299)
- Testing
- Oral
- Where
- Thailand
- Volunteers
- 320 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
SARS-CoV2 Infection, COVID-19, Gut Microbiota, Mucosal Response, Children
COVID-19 and Intestinal Microbiota in Children
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. It appears to cause only mild to moderate upper respiratory symptoms in children, in addition to gastrointestinal symptoms resulting from its penetration into intestinal…
- Trial name
- NCT06503887
- Testing
- Stool sample collection
- Where
- Lebanon
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Saint-Joseph University
Acute Respiratory Distress Syndrome
Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU
Renal damage in patients hospitalized for ARDS in the ICU can also be related to multiple causes including, but not limited to, the consequences of hemodynamic fluctuations in these patients or the use of nephrotoxic drugs…
- Trial name
- PR-Covid-19 (NCT04385004)
- Where
- France
- Volunteers
- 320 people
- Sponsor
- University Hospital, Strasbourg, France
Adult Patients With Lesions on Fingers or Toes
Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome
The recent and unexpected occurrence of patients with the development of skin lesions on the hands and/ or feet has been described recently.
- Trial name
- ACROCOVID (NCT04590209)
- Testing
- Blood sampling, Skin biopsy
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Volunteers
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
- Trial name
- NCT04679909
- Testing
- AdCOVID
- Where
- 6 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Covid-19, Pneumonia
The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19
The aim of this study is to evaluate the efficacy of pulmonary physiotherapy on respiratory functions in hospitalized patients with Novel Coronavirus 2019 pneumonia.
- Conditions
- Covid-19, Pneumonia, SARS Pneumonia
- Trial name
- NCT04357340
- Testing
- Pulmonary Physiotherapy Techniques
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Influenza, SARS-CoV-2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65…
- Trial name
- NCT06508320
- Testing
- mRNA-1083
- Where
- 17 sites in United States, Canada
- Volunteers
- 931 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Artificial Intelligence - SARS-CoV-2 (COVID-19) Risk Evaluation
The management of COVID-19 patients in overwhelmed hospital facing the pandemic is a clinical challenge. The improvement of decision making may allow a better allocation of available resources and a better treatment of patients…
- Trial name
- AI-SCoRE (NCT04834934)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS San Raffaele
Covid-19
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
The study is designed as a randomized, controlled, multi-center open-label trial to compare standard-of-care (SOC) treatment with SOC + anakinra or SOC + tocilizumab treatment in hospitalized adult subjects who are diagnosed with…
- Trial name
- NCT04412291
- Testing
- Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe, Standard-of-care treatment
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
SARS-CoV-2 Infection, COVID-19
Effect of COVID-19 Lockdown on Alcohol and Tobacco Use in Two Chilean Universities
This is a longitudinal study of participants from two university communities in Chile. The primary objective is to examine the effect of a regional lockdown on alcohol and tobacco use, using a difference-in-difference analysis to…
- Trial name
- NCT05069090
- Testing
- Lockdown and other social distancing measures
- Where
- 2 sites in Chile
- Volunteers
- 1,038 people, healthy volunteers welcome
- Sponsor
- Universidad de La Frontera
Aged
Effects of the Programme Developed for Sedentary Elderly in the COVID-19 Pandemic: Mobile Interventional Study
The purpose of all these applications is the same: people keep distance and isolate themselves from those in risk groups and patients.
- Trial name
- NCT05110560
- Testing
- "Stay at Home Take a Step Program (SHTSP)"
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Namik Kemal University
Covid19, Vaccine
Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial
ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories.
- Conditions
- Covid19, Vaccine, Immunogenicity
- Trial name
- NCT04961385
- Testing
- Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Covid19
Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions
REMPAR EHPAD study addresses environmental and managerial factors associated with an outbreak of COVID 19 in French Long Term Care Institutions in the spring of 2020.
- Trial name
- REMPAR-EHPAD (NCT04579289)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Rennes University Hospital
Stroke, Acute
Covid-19 Epidemic on Acute Stroke Management
The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2.
- Trial name
- Stroke-Covid19 (NCT04370197)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
COVID-19 Virus Disease
Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.
The purpose of this study is to evaluate the efficacy and safety of CaD in reducing SARS-CoV-2 viral load in non-hospitalized adult patients diagnosed with COVID-19, documented with a positive SARS-CoV-2 PCR and with the…
- Trial name
- COVID-19 (NCT05305508)
- Testing
- Calcium Dobesilate, Mannitol
- Where
- Switzerland
- Volunteers
- 74 people
- Sponsor
- Hervé SPECHBACH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.